Scinai Immunotherapeutics (SCNI) Cash & Equivalents (2015 - 2026)

Scinai Immunotherapeutics (SCNI) has 12 years of Cash & Equivalents data on file, last reported at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 257776.41% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (up 257776.41% YoY), and the FY2025 full-year result was $1.7 million, down 15.43% from the prior year.
• Cash & Equivalents rose to $3.0 billion in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $3.0 billion in Q1 2026 to a low of $1.1 million in Q2 2025.
• A 5-year average of $192.4 million and a median of $6.7 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 77.39% in 2024 and jumped 257776.41% in 2026, its largest moves.
• Tracing SCNI's Cash & Equivalents over 5 years: stood at $14.1 million in 2022, then slumped by 65.4% to $4.9 million in 2023, then plunged by 59.67% to $2.0 million in 2024, then dropped by 15.43% to $1.7 million in 2025, then surged by 178286.51% to $3.0 billion in 2026.
• Business Quant data shows SCNI's Cash & Equivalents at $3.0 billion in Q1 2026, $1.7 million in Q4 2025, and $1.1 million in Q2 2025.